ERKEK MEME KANSERİ CERRAHİ DENEYİMİMİZ

Year 2022, Volume: 29 Issue: 2, 255 - 259, 30.06.2022

İsmail Zihni Mustafa Tercan Muhammed Selim Bodur Bilal Turan İsa Karaca Mümtaz Erakın Girayhan Çelik İsa Sözen Mehmet Sabuncuoglu Recep Çetin

https://doi.org/10.17343/sdutfd.955035

Abstract

Amaç
Erkek Meme Kanseri nadir görülen bir hastalıktır. İnsidansı
son yıllarda artmakta, ancak sağkalım sonuçları
iyileşmektedir. Prospektif randomize çalışmaların
eksikliği nedeniyle, kadın meme kanseri kılavuzlarına
göre tedavisi ve takibi yapılmaktadır. Ancak kendine
özgü anatomi ve fizyolojisi nedeniyle hastalığın seyrinde
farklılıklar olabileceği düşünülmektedir.
Gereç ve Yöntem
Süleyman Demirel Üniversitesi Tıp Fakültesi Cerrahi
Onkoloji Kliniği’ nde Ocak 2011 – Ocak 2020 tarihleri
arasında meme kanseri nedeniyle opere edilen erkek
hastaların verileri retrospektif olarak değerlendirildi.
Adenokarsinom dışındaki meme patolojileri çalışmaya
dahil edilmedi.
Bulgular
Çalışmaya 7 hasta dahil edildi. Aynı süre içerisinde
847 kadın hasta görülürken, erkek hasta oranı % 0,8
idi. Tüm hastalara total mastektomi ile birlikte level 1,
2, 3 aksiller diseksiyon yapıldı. Patoloji sonuçları değerlendirildiğinde;
1 (% 14,2) hastada evre 1, 2 (%
28,5) hastada evre 2, 3 (% 42,8) hastada evre 3, 1 (%
14,2) hastada evre 4 hastalık olduğu görüldü. Genel
sağkalım ortanca değeri 48 ay (min: 35 - max: 53 )
olarak saptandı.
Sonuç
Erkek meme kanserinin aynı evredeki hastalarda
prognozunun kadın meme kanserinden daha kötü
olmadığı gösterilmiştir. Ancak geç tanı, tedaviye
uyumsuzluk ve standardizasyon problemleri nedeniyle
pratikte daha kötü prognoz söz konusudur. Erkek
meme kanseri konusunda farkındalığın artırılması ve
yapılacak geniş çaplı prospektif randomize çalışmalar
neticesinde tedavinin erkek meme kanserine özgü,
standardize edilmesi ile daha iyi sonuçlara ulaşılabileceğini
düşünüyoruz.

Keywords

erkek meme kanseri,, mastektomi, meme kanseri

OUR MALE BREAST CANCER SURGERY EXPERIENCE

Abstract

Objective
Male breast cancer is a rare disease. Its incidence has
increased in recent years, but survival outcomes are
improving. Due to the lack of prospective randomized
trials, it is treated and followed up according to female
breast cancer guidelines. However, it is thought that
there may be differences in the course of the disease
due to its unique anatomy and physiology.
Materials and Methods
The data of male patients who were operated for
breast cancer in Süleyman Demirel University
Medical Faculty Surgical Oncology Clinic between
January 2011 and January 2020 were evaluated
retrospectively. Breast pathologies other than
adenocarcinoma were not included in the study.
Results
Seven patients were included in the study. During the
same period, 847 female patients were seen, while the
rate of male patients was % 0,8. Level 1, 2, 3 axillary
dissection was performed in all patients along with
total mastectomy. When the pathology results were
evaluated, it was seen that 1 (14,2 %) patient had stage
1, 2 (28,5 %) patient stage 2, 3 (42,8 %) patient stage 3,
1 (14,2 %) patient stage 4 disease. The median overall
survival was 48 months (min: 35 - max: 53).
Conclusion
It has been shown that the prognosis of male breast
cancer in patients at the same stage is not worse
than female breast cancer. However, in practice,
the prognosis is worse due to late diagnosis, noncompliance
with treatment and standardization
problems. We believe that better results can be
achieved by raising awareness about male breast
cancer and standardizing treatment specific to male
breast cancer as a result of large - scale prospective
randomized trials.

Keywords

breast cancer,, male breast cancer, mastectomy

References

• [1] Romics L., O'Brien M. E., Relihan N., O'Connell F., Redmond H. P. (2009). Intracystic papillary carcinoma in a male as a rare presentation of breast cancer: a case report and literature review. Journal of Medical Case Reports, 3(1), 13.
• [2] Korde L. A., Zujewski J. A., Kamin L., Giordano S., Domchek S., Anderson W. F., et all (2010). Multidisciplinary meeting on male breast cancer: summary and research recommendations. Journal of Clinical Oncology, 28(12), 2114.
• [3] Anderson W. F., Jatoi I., Tse J., Rosenberg P. S. (2010). Male breast cancer: a population-based comparison with female breast cancer. Journal of Clinical Oncology, 28(2), 232.
• [4] Leon - Ferre R. A., Giridhar K. V., Hieken T. J., Mutter R. W., Couch F. J., Jimenez R. E. et all (2018). A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 37(4), 599-614.
• [5] Salehi A., Zeraati H., Mohammad K., Mahmoudi M., Talei A. R., Ghaderi A., et all (2011). Survival of male breast cancer in Fars, South of Iran. Iranian Red Crescent Medical Journal, 13(2), 99.
• [6] Auvinen A., Curtis R. E., Ron E. (2002). Risk of subsequent cancer following breast cancer in men. Journal of the National Cancer Institute, 94(17), 1330-1332.
• [7] Dong C., Hemminki K. (2001). Second primary breast cancer in men. Breast cancer research and treatment, 66(2), 171.
• [8] Baojiang L., Tingting L., Gang L., Li Z. (2012). Male breast cancer: A retrospective study comparing survival with female breast cancer. Oncology letters, 4(4), 642-646.
• [9] Metin Y., Aydın İ., Mikdat B. (2016). Male Breast Cancer. J Breast Health, 12, 1-8.
• [10] Nahleh Z. A., Srikantiah R., Safa M., Jazieh A. R., Muhleman A., Komrokji R. (2007). Male breast cancer in the veterans affairs population: a comparative analysis. Cancer: Interdisciplinary International Journal of the American Cancer Society, 109(8), 1471-1477.
• [11] Gnerlich J. L., Deshpande A. D., Jeffe D. B., Seelam S., Kimbuend, E., Margenthaler J. A. (2011). Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in - stage migration. Annals of surgical oncology, 18(7), 1837-1844.
• [12] Foerster R., Foerster F. G., Wulff V., Schubotz B., Baaske D., Wolfgarten M., Rudlowski C. (2011). Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC cancer, 11(1), 335.
• [13] Borgen P. I., Senie R. T., McKinnon W. M., & Rosen P. P. (1997). Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Annals of surgical oncology, 4(5), 385-388.
• [14] Oger A. S., Boukerrou M., Cutuli B., Campion L., Rousseau E., Bussières E., et all. (2015). Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases. Gynecologie, obstetrique & fertilite, 43(4), 290-296.
• [15] Zongo N., Ouédraogo S., Korsaga - Somé N., Somé O. R., Naïma G. O., Ouangré E., et all. (2018). Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso). World journal of surgical oncology, 16(1), 4.
• [16] Bourhafour M., Belbaraka R., Souadka A., M'rabti H., Tijami F., Errihani H. (2011). Male breast cancer: a report of 127 cases at a Moroccan institution. BMC research notes, 4(1), 219.
• [17] Al Awayshih M. M., Nofal M. N., Yousef A. J. (2019). Modified Radical Mastectomy for Male Breast Cancer. The American journal of case reports, 20, 1336.
• [18] Nguyen T., Cowher M. (2012, May). Demand for breast-conserving surgery among male breast cancer patients. In Annals of surgical oncology (Vol. 19, pp. 91-92). 233 Spring St, New York, NY 10013 USA: Springer.
• [19] Parker P. A., Youssef A., Walker S., Basen - Engquist K., Cohen L., Gritz E. R., et all. (2007). Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Annals of surgical oncology, 14(11), 3078-3089.
• [20] Nordman I. C., Dalley D. N. (2008). Breast Cancer in Men—Should Aromatase Inhibitors Become First‐Line Hormonal Treatment?. The breast journal, 14(6), 562-569.
• [21] Mauras N., Hayes V. Y., Klein K. O. (1999). Estrogen suppression in males: metabolic effects. Pediatric Research, 45(7), 94-94.
• [22] Pemmaraju N., Munsell M. F., Hortobagyi G. N., Giordano S. H. (2012). Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Annals of oncology, 23(6), 1471-1474.
• [23] Moredo Anelli T. F., Anelli A., Tran K. N., Lebwohl D. E., Borgen P. I. (1994). Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients. Cancer, 74(1), 74-77.
• [24] Fentiman I. S. (2018). Surgical options for male breast cancer. Breast cancer research and treatment, 172(3), 539-544.
• [25] Xu S., Yang Y., Tao W., Song Y., Chen Y., Ren Y., et all. (2012). Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast cancer research and treatment, 136(2), 495-502.
• [26] Cloyd J. M., Hernandez - Boussard T., Wapnir I. L. (2013). Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983–2009. Annals of surgical oncology, 20(5), 1545-1550.
• [27] Jardel P., Vignot S., Cutuli B., Creisson A., Vass S., Barranger E., et all. (2018). Should adjuvant radiation therapy be systematically proposed for male breast cancer? A systematic review. Anticancer research, 38(1), 23-31.
• [28] Cardoso F., Bartlett J. M. S., Slaets L., Van Deurzen C. H. M., van Leeuwen - Stok E., Porter P., et all. (2018). Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of oncology, 29(2), 405-417.
• [29] Ruddy K. J., Winer E. P. (2013). Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Annals of oncology, 24(6), 1434-1443.